Xcout Intel
Tubulis
Tubulis is a biotechnology organization headquartered in Munich that generates uniquely matched antibody-drug conjugates with superior biophysical properties.
Subscribe to see Tubulis’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tubulis at a glance
Tubulis is a biotechnology company headquartered in Germany. It has raised at least $397.7M across the 3 funding rounds on record. Its most recent funding round, Series C, raised $322.5M in October 2025. Xcout tracks 14 named people at Tubulis, including Dominik Schumacher (CEO and Co-founder).
Tubulis leadership
- Dominik SchumacherCEO and Co-founder
- Dr. Dominik SchumacherCEO
- Dr. Jonas Helma-SmetsCSO
- Dr. Armin WeidmannSenior Vice President Quality
- Dr. Moetaz B. AlbizemSenior Vice President and Head of Clincal Operations
- Dr. Olivier MarcqSenior Vice President CMC
8 more named people on record for Tubulis, with roles, board committees and tenure — see the full roster →
Tubulis funding rounds
At least $397.7M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $322.5M | 13 named | |
| Series B | $63M | 1 named | |
| — | $12.2M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Tubulis news
Investors
Tubulis competitors
A few of Tubulis's closest competitors — see the full list of competitors and alternatives →
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
Get Tubulis's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Tubulis in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access